Targeting CSPG4 using monoclonal antibodies decreases mesothelioma cell invasiveness as well, and it has been proposed as a potential target for the treatment of mesothelioma, breast cancer, and melanoma (Wang et al., 2010; Price et al., 2011; Yu et al., 2011; Rivera et al., 2012). This evidence concerns the gene CSPG4 and melanoma.